Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FJCZS
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AMG-172
|
|||||
| Synonyms |
AMG 172; AMG172; antiCD27L-MCC-DM1
Click to Show/Hide
|
|||||
| Organization |
Amgen, Inc.
|
|||||
| Drug Status |
Terminated in phase 1
|
|||||
| Indication |
In total 1 Indication(s)
Renal cell carcinoma [ICD11:2C90]
Terminated in phase 1
|
|||||
| Drug-to-Antibody Ratio |
3.5
|
|||||
| Antibody Name |
Anti-CD70 AMG172 mAb
|
Antibody Info | ||||
| Antigen Name |
CD70 antigen (CD70)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
| Combination Type |
Emtansine
|
|||||
| Puchem SID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.